Sonoma Pharmaceuticals, Inc. (SNOA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 03-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 7M 14M 21M FY17: 12.8M FY18: 16.7M FY19: 19M FY20: 17.9M FY21: 18.6M FY22: 12.6M FY23: 13.3M FY24: 12.7M FY25: 14.3M FY26: 19.5M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26

Gross Profit Annual

0 3.5M 7M 10.5M FY17: 5.7M FY18: 7.3M FY19: 8.9M FY20: 8.1M FY21: 6.6M FY22: 4M FY23: 4.5M FY24: 4.7M FY25: 5.5M FY26: 7.4M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26

Operating Income Annual

-15M -10M -5M 0 5M 10M 15M FY17: -13M FY18: -14.2M FY19: -11.3M FY20: -7.4M FY21: -3.4M FY22: -5.9M FY23: -4.6M FY24: -4.7M FY25: -3.7M FY26: -2.5M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26

Net Income Annual

-15M -10M -5M 0 5M 10M 15M FY17: 9.3M FY18: -14.3M FY19: -11.8M FY20: -3.3M FY21: -4M FY22: -5.1M FY23: -5.2M FY24: -4.8M FY25: -3.5M FY26: -3.2M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26

Cost of Revenue Annual

0 5M 10M 15M FY17: 7.2M FY18: 9.3M FY19: 10.1M FY20: 9.8M FY21: 12.1M FY22: 8.6M FY23: 8.8M FY24: 8M FY25: 8.8M FY26: 12.1M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26

Operating Cash Flow Annual

-15M -10M -5M 0 5M 10M 15M FY17: -8.2M FY18: -12.4M FY19: -11.7M FY20: -4.6M FY21: -3.4M FY22: -4.2M FY23: -6.2M FY24: -2.4M FY25: -88K FY26: -3.9M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26

Free Cash Flow Annual

-15M -10M -5M 0 5M 10M 15M FY17: -8.6M FY18: -12.6M FY19: -11.8M FY20: -4.8M FY21: -3.6M FY22: -4.4M FY23: -6.4M FY24: -2.4M FY25: -168K FY26: -4.1M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 3.5M 7M 10.5M FY13: 5M FY14: 6.9M FY15: 9.7M FY22: 2.7K FY23: 3.4M FY24: 455K FY25: 1.2M FY26: 1.7M FY13 FY14 FY15 FY22 FY23 FY24 FY25 FY26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q3 '12: -0.26 Q4 '12: -1.86 Q1 '13: -1.92 Q2 '13: -2.22 Q3 '13: -2.50 Q4 '13: -1.29 Q1 '14: -1.41 Q2 '14: -1.29 Q3 '14: -1.01 Q4 '15: -0.84 Q1 '16: -1.60 Q2 '16: -2.06 Q3 '16: -2.33 Q4 '16: -4.91 Q1 '17: -4.75 Q2 '17: -4.67 Q3 '17: 0.13 Q4 '17: 2.20 Q1 '18: 1.99 Q2 '18: 1.78 Q3 '18: -2.79 Q4 '19: -13.27 Q1 '20: -7.74 Q2 '20: -4.73 Q3 '20: -3.08 Q4 '20: -2.20 Q1 '21: -2.61 Q2 '21: -1.63 Q2 '24: -6.94 Q3 '24: -7.91 Q4 '24: -10.63 Q1 '25: -11.68 Q2 '25: -6.52 Q3 '25: -5.56 Q4 '25: -2.95 Q1 '26: -2.37 Q2 '26: -2.10 Q3 '26: -1.95 Q4 '26: -1.89 Q1 '27: -1.22 Q3 '13 Q4 '15 Q1 '17 Q2 '18 Q3 '20 Q3 '24 Q4 '25 Q1 '27

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.